A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease

Inclusion Criteria

• •You may be eligible for this study if you:
• •Are 18 years of age or older.
• •Are seropositive for antibodies against B. burgdorferi antigens by Western Blot at enrollment.
• •Have documented history of acute Lyme disease.
• •Have had a rash (erythema migrans) that resembles a bullseye. This skin aberration usually occurs after a tick bite in late spring, summer or early fall and is sometimes accompanied by fatigue, fever, headache, mild stiff neck, arthralgia or myalgia.
• •Have had one or more clinical features typical of Lyme disease acquired in the United States (see technical summary).
• •Have had one or more of the following symptoms and conditions that have persisted for at least 6 months (but less than 12 years) and are not attributable to another cause or condition: a) widespread musculoskeletal pain and fatigue that began coincident with or within 6 months following initial infection with B. burgdorferi. b) certain neurologic symptoms including memory impairment and nerve pain within 6 months following initial infection with B. burgdorferi.
• •Have had a physician-documented history of prior antibiotic treatment with a currently recommended antibiotic regimen.